Study of Nivolumab plus Ipilimumab plus Sargramostim Versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (EA6141)
Study of Nivolumab plus Ipilimumab plus Sargramostim Versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (EA6141)
Trial Category:
Melanoma
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
